Novavax has begun a late-stage trial of its experimental COVID-19 vaccine in the UK, which could support filings for a licence in the UK, EU and other countries.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs says the company is at a pivot point.

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX. Type a few ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

The purpose of the OWS grant was to enable Novavax to: ...complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 ...

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX. Type a few ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax, Inc. (NYSE:NVAX ... received clearance from the U.S. FDA to proceed with a Phase 3 immunogenicity trial for both the CIC and standalone influenza vaccine candidates.

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...